bioRxiv · 10.1101/2022.12.15.520590
Activation of the P2RX7/IL-18 pathway in immune cells inhibits lung fibrosis
Abstract
Idiopathic pulmonary fibrosis (IPF) is an aggressive interstitial lung disease associated with progressive and irreversible deterioration of respiratory functions that lacks curative therapies. Despite IPF being associated with a dysregulated immune response, current antifibrotics aim only at limiting fibroproliferation. We show here that the P2RX7/IL-18/IFNG axis is downregulated in IPF patients and that P2RX7 has immunoregulatory functions. Using our positive modulator of P2RX7, we show that activation of the P2RX7/IL-18 axis in immune cells limits lung fibrosis progression in a mouse model by favoring an anti-fibrotic immune environment, with notably an enhanced IL-18-dependent IFN-{gamma} production by lung T cells leading to a decreased production of IL-17 and TGF{beta}. Overall, we show the ability of the immune system to limit lung fibrosis progression by targeting the immunomodulator P2RX7. Hence, treatment with a small activator of P2RX7 may represent a promising strategy to help patients with lung fibrosis.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Janho dit Hreich, S., Juhel, T., Leroy, S., Brau, F., hofman, v., hofman, p., Vouret-Craviari, V.. 2022-12-18. Activation of the P2RX7/IL-18 pathway in immune cells inhibits lung fibrosis. https://doi.org/10.1101/2022.12.15.520590
Cite the original work for its findings. Save a collection to share your selection of sources.